@aveek18@zabrams@JamesEvansMS@JoCoxFoundation@EducationUoM@Matt_VickersMP Prof Pam Qualter starts us off - "loneliness is a subjective experience", she says, which occurs when we lack good quality relationships with others. "We're not talking about social isolation", though loneliness has the same effects on physical & mental health
Discussion on how renewables can catalyse levelling up at panel at #CPC22
Our chair @AkashPaun introduces the panel. We'll be discussing if decarbonisation is working and if the drive to net zero can deliver long term energy security.
Our first speaker is @NinaSkorupska
There are around 148k people working in the renewable energy sector. Nina describes how renewable energy and clean technology plays an important role.
We start with our chair @stkaye introducing our panel.
Our panel today will discuss 'is smart tech a threat to your privacy and security.'
One of the preoccupations of todays conversation will be to debate if legislation has kept up with technology.
There is the real world that is becoming more digital and the digital world becoming more tangible @stkaye of @reformthinktank tells us.
He describes the difficult space between prevention and freedom regarding digital crimes.
@KevinASchofield@RobinMillarMP@SymaCullasy@OfficialUoM@RichardALJones@DodsEvents "In my view, universities are crucial anchor institutions", says Lord Willetts, though he notes that more can be done - he says a well-tailored, investable proposition for domestic & international investors is needed, which brings together strengths in research and students
Prof Jo Neill (@b_neuro) is about to give evidence to the @CommonsHomeAffs Select Committee, on the health, economic, and research cases for rescheduling #psilocybin for #mentalhealth treatment.
@b_neuro@CommonsHomeAffs On whether the UK's current drug regulations are fit for purpose, Prof Neill says "clearly not", as they're not based on evidence, and inhibits research & innovation by throwing up barriers to research.
@b_neuro@CommonsHomeAffs Schedule 1 is reserved for drugs with "no medicinal value and causes a great deal of harm", but the evidence is clear psilocybin *has* medicinal value, and does not cause significant harm, especially when used in clinical settings.